Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Receivables - Accured: 2024

Historic Receivables - Accured for SAB Biotherapeutics (SABS) over the last 1 years, with Dec 2024 value amounting to $55,000.

  • SAB Biotherapeutics' Receivables - Accured rose 477.04% to $560,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $560,000, marking a year-over-year increase of 477.04%. This contributed to the annual value of $55,000 for FY2024, which is N/A change from last year.
  • According to the latest figures from FY2024, SAB Biotherapeutics' Receivables - Accured is $55,000.
  • SAB Biotherapeutics' Receivables - Accured's 5-year high stood at $55,000 during FY2024, with a 5-year trough of $55,000 in FY2024.
  • In the last 1 years, SAB Biotherapeutics' Receivables - Accured had a median value of $55,000 in 2024 and averaged $55,000.